Vera Therapeutics (VERA) Total Non-Current Liabilities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Total Non-Current Liabilities data on file, last reported at $120.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $120.2 million; the trailing twelve-month figure through Mar 2026 stood at $120.2 million (changed N/A YoY), and the FY2025 full-year result was $128.3 million, up 63.38% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $120.2 million, down from $128.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $128.3 million in Q4 2025 and bottomed at $25.4 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $59.9 million (2023), against an average of $64.9 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities jumped 565.32%; it then gained 6.73% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $54.2 million in 2022, then jumped by 35.64% to $73.6 million in 2023, then rose by 6.73% to $78.5 million in 2024, then surged by 63.38% to $128.3 million in 2025, then dropped by 6.33% to $120.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $120.2 million (Q1 2026), $128.3 million (Q4 2025), and $78.5 million (Q4 2024), per Business Quant data.

Peer Comparison